We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Isatuximab‐carfilzomib‐dexamethasone immediately after failing of the quadruplet Daratumumab‐bortezomib‐lenalidomide‐dexamethasone (Dara‐VRD): Striking response with no washout in a newly diagnosed multiple myeloma.
- Authors
Gil‐Fernández, Juan José; García Ramírez, Patricia; Callejas Charavía, Marta
- Abstract
This article discusses the case of a patient with newly diagnosed multiple myeloma who had a poor response to the quadruplet combination of daratumumab-bortezomib-lenalidomide-dexamethasone (Dara-VRD). The patient was then treated with the combination of isatuximab-carfilzomib-dexamethasone (ISA-KD) without a washout period, and achieved a rapid and deep response. The article highlights the controversy surrounding the use of isatuximab after daratumumab and discusses the different mechanisms of action and drug resistance between the two anti-CD38 monoclonal antibodies. The authors suggest that the ISA-KD combination may be an excellent rescue therapy for patients with poor responses to Dara-VRD.
- Subjects
MULTIPLE myeloma; QUADRUPLETS; BISPECIFIC antibodies; MONOCLONAL gammopathies
- Publication
Clinical Case Reports, 2024, Vol 12, Issue 1, p1
- ISSN
2050-0904
- Publication type
Case Study
- DOI
10.1002/ccr3.8449